loading page

Efficacy and Safety of Left Atrial Low-Voltage Area-Guided Catheter Ablation of Atrial Fibrillation: An Updated Systematic Review and Meta-analysis
  • +6
  • Xiaoping Li,
  • Yaqiong Zhou,
  • Hamin Zhang,
  • Peng Yan,
  • Fengpeng Jia,
  • Xinquan Wang,
  • Dan Wang,
  • Peng Zhou,
  • Peijian Wang
Xiaoping Li
University of Electronic Science and Technology of China School of Electronic Science and Engineering

Corresponding Author:[email protected]

Author Profile
Yaqiong Zhou
Chengdu Medical College
Author Profile
Hamin Zhang
Chengdu Medical College
Author Profile
Peng Yan
Chengdu Medical College
Author Profile
Fengpeng Jia
The First Affiliated Hospital of Chongqing Medical University
Author Profile
Xinquan Wang
Chengdu Medical College
Author Profile
Dan Wang
Chengdu Medical College
Author Profile
Peng Zhou
Chengdu Medical College
Author Profile
Peijian Wang
Chengdu Medical College
Author Profile

Abstract

Aims: This study aimed to evaluate the efficacy and safety of LVA-guided substrate modification catheter ablation in patients with AF. Methods: Systematic searches of the PubMed, EMBASE, and Cochrane databases were performed from inception to February 2022 for all available studies. The effect estimates were combined with the Mantel–Haenszel random-effects model. Subgroup analyses, sensitivity analysis and meta-regression were performed to explore the sources of statistical heterogeneity. Results: A total of 16 studies involving 1931 subjects (mean age: 61±10 years, 69% male) were identified. All studies included patients with paroxysmal AF, nonparoxysmal AF, or both. At a mean follow-up of 18.9 months, patients who underwent LVA ablation had significantly higher freedom from all-atrial tachycardia recurrence than patients who underwent control ablation (67.6% vs. 48.9%, risk ratios [RR] 0.66, 95% confidence interval [CI]: 0.57-0.76, P<0.001), with 34% relative risk and 18.7% absolute risk reductions in all-atrial tachycardia recurrence. Six studies assessed the incidence of stroke/transient ischemic attacks (TIAs) between the 2 groups. However, no stroke/TIA occurred in most of these studies. Furthermore, the rates of acute procedural complications were not significantly different between the 2 groups (LVA ablation 2.4% vs. control ablation 3.3%, RR 0.56, 95% CI: 0.30-1.07, P =0.08). Conclusion: LVA-guided substrate modification ablation appears to have a significant benefit in improving freedom from all-atrial tachycardia recurrence. Importantly, this benefit is achieved without a significant increase in the rates of acute procedural complications or cerebral thromboembolic events.